That is my order ;) - my final OPK investment. I bought 25K shares yesterday.
All these days, i had only options - 2000 contracts (June 2014 thru Jan 2016).
what it takes to nurture a company and get it to the next level. This is no longer a start up - that tag has been around this company' neck for too long now.
When they try to do too many things with hardly any money to support these initiatives, you know they are throwing darts in the dark hoping to hit bull's eye. I wont be surprised if they waste all the money they have raised by giving themselves nice pay/perks, without getting anything noteworthy done. They will comeback again in about 18 months and will be issuing more shares.
Any idea when Frost will make his move? especially with Rayladee news up in June or even earlier His buys are certainly big and frequent this year....
Frost bought 110,600 shares yesterday, April 14, 2014
He is going for the kill - anytime now and possibly before Rayladee news in June
It is called the Dirty Dan effect - PPS drops, volume drops even on a day when the market is moving up triple digits. Dan is not the man for the job
I never get tired of reading the same headline from you everyday - a new number every day!!
Exciting indeed and shorts are living in fool's paradise.
What new dirty tricks does Dirty Dan have so that he can grind shareholders to the dust? At this rate we will be at $.01 pps pre-split equivalent
OPK is surviving and it will thrive. Take heart longs;
Shorts do not know what is going to hit them. They may mock at us during these dark days, but very soon they will be banished to a distant black hole.
Long Strong and Cheerful
Reading between the lines of today's PR says it all. They are ready for Rayaldee launch
Mr. Toner has over 30 years of pharmaceutical experience with a history of developing effective marketing strategies for new drugs to treat chronic kidney disease (CKD). Mr. Toner was previously Senior Director of Global Marketing at Reata Pharmaceuticals with responsibility for the marketing strategy supporting a new innovative therapy for CKD in type 2 diabetes patients; Executive Director of Marketing at AMAG Pharmaceuticals where he led the launch of Feraheme®, an iron replacement product for dialysis patients; and Director of Renal Commercial Development at Abbott Laboratories with responsibility for Zemplar®. Zemplar became the most successful vitamin D therapy for secondary hyperparathyroidism (SHPT) in the US. Mr. Toner also serves as a member of the Board of the American Association of Kidney Disease Patients (AAKP)
Dr. Strugnell has extensive experience in the research and development of new vitamin D drugs for CKD patients with vitamin D insufficiency. Prior to OPKO, he was Associate Scientific Director at Genzyme Renal and Associate Director of Preclinical Research at Bone Care International where he managed research supporting Hectorol®, the first modern vitamin D product approved in the US for SHPT in pre-dialysis patients. Dr. Strugnell received his PhD degree from Queens University under the direction of Dr. Glenville Jones, and completed a post-doctoral fellowship at the University of Wisconsin-Madison under the direction of Dr. Hector DeLuca. Drs. Jones and DeLuca are internationally regarded experts on vitamin D metabolism.
Scott and Steve are powerful additions to our management team," said Dr. Charles W. Bishop, CEO of OPKO Renal. "These two individuals have a remarkable understanding of the renal market and provide unparalleled experience in developing and launching proprietary renal disease products.
And then Frost welcomes them hinting the good news
Why am I having a hunch that the results will be out sometime in May instead of June... They might as well end the trial if the results are way better than what is required per the protocol. It has happened with other pharma before , If I am not mistaken a few months back.
Keeping fingers crossed....
hey tiny - Is the name an indicator for the size of your brain or size of your nuts??
As far as your question is concerned, you will find answers very soon - no point in jumping the gun. .
If you have doubts, then that is OK - you need to go ahead and short OPK to justify your doubts. Ask Bryan, he has all the numbers and may help you along the way.
and it closes at 9.71 - :)
oh Bryan is missing in action today and the silence is deafening - LOL